Somatostatin Receptor Subtype 2A Expression and Genetics in 184 Paragangliomas: a Single Center Retrospective Observational Study

Overview

Journal Endocrine

Specialty Endocrinology

Date 2024 Feb 2

PMID 38306009

Authors

Yanting Shen

Yu Luo

Minghao Li

Rongkui Luo

Lingli Chen

Xin Gao

Jingjing Jiang

Yujun Liu

Zhiqiang Lu

Jing Zhang

Affiliations

Soon will be listed here.

Abstract

Purpose: Adrenal and extra-adrenal paragangliomas (PGLs) are a group of neuroendocrine tumors (NETs) with strong heterogeneity, which often express somatostatin receptor subtype 2 A (SSTR2A). However, the association between SSTR2A expression and genetic status of PGLs remains unclear. The purpose of the study was to identify whether various pathogenic variants (PVs) had an impact on SSTR2A expression in PGLs.

Methods: This retrospective study included 184 patients with pathologically confirmed PGLs. The immunohistochemical expression of SSTR2A were studied in 184 tumors and PVs were tested in 159 tumor samples. Clinical and genetic data were compared in SSTR2A positive and negative PGLs.

Results: SSTR2A was positive in 63.6% (117/184) of all tumors. PGLs with negative SSTR2A were more likely to be extra-adrenal (37.0% vs 18.0%; P = 0.005) and exhibited a considerably greater proportion of PVs (75.4% vs. 49.0%; P = 0.001) than those with positive SSTR2A. Compared to those without PVs, a higher proportion of PGLs with PVs in cluster 1B (P = 0.004) and cluster 2 (P = 0.004) genes, especially VHL (P = 0.009), FGFR1 (P = 0.010) and HRAS (P = 0.007), were SSTR2A negative. SSTR2A was positive in all tumors (4/4) with SDHx PVs and in 87.5% (7/8) of metastatic PGLs.

Conclusions: SSTR2A negativity was correlated with extra-adrenal tumor location and PVs in cluster 1B and cluster 2 genes such as VHL, FGFR1 and HRAS. Immunohistochemistry of SSTR2A should be taken into consideration in the personalized management of PGLs.

Citing Articles

Agonists, Antagonists and Receptors of Somatostatin: Pathophysiological and Therapeutical Implications in Neoplasias.

Periferakis A, Tsigas G, Periferakis A, Tone C, Hemes D, Periferakis K Curr Issues Mol Biol. 2024; 46(9):9721-9759.

PMID: 39329930 PMC: 11430067. DOI: 10.3390/cimb46090578.

References

Mete O, Asa S, Gill A, Kimura N, de Krijger R, Tischler A . Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol. 2022; 33(1):90-114. DOI: 10.1007/s12022-022-09704-6. View

Reubi J, Waser B, Khosla S, Kvols L, Goellner J, Krenning E . In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 1992; 74(5):1082-9. DOI: 10.1210/jcem.74.5.1349024. View

Reubi J . Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003; 24(4):389-427. DOI: 10.1210/er.2002-0007. View

Ullrich M, Richter S, Liers J, Drukewitz S, Friedemann M, Kotzerke J . Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models. Theranostics. 2023; 13(1):278-294. PMC: 9800739. DOI: 10.7150/thno.77918. View

Taieb D, Hicks R, Hindie E, Guillet B, Avram A, Ghedini P . European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019; 46(10):2112-2137. PMC: 7446938. DOI: 10.1007/s00259-019-04398-1. View

Reubi J, Schar J, Waser B, Wenger S, Heppeler A, Schmitt J . Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000; 27(3):273-82. DOI: 10.1007/s002590050034. View

Janssen I, Blanchet E, Adams K, Chen C, Millo C, Herscovitch P . Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma. Clin Cancer Res. 2015; 21(17):3888-95. PMC: 4558308. DOI: 10.1158/1078-0432.CCR-14-2751. View

Janssen I, Chen C, Zhuang Z, Millo C, Wolf K, Ling A . Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes. J Nucl Med. 2017; 58(8):1236-1242. PMC: 5537614. DOI: 10.2967/jnumed.116.187690. View

Leijon H, Remes S, Hagstrom J, Louhimo J, Maenpaa H, Schalin-Jantti C . Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas. Hum Pathol. 2018; 86:66-75. PMC: 8192062. DOI: 10.1016/j.humpath.2018.11.020. View

10.

Elston M, Meyer-Rochow G, Conaglen H, Clarkson A, Clifton-Bligh R, Conaglen J . Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas. Hum Pathol. 2015; 46(3):390-6. DOI: 10.1016/j.humpath.2014.11.012. View

11.

Patel M, Tena I, Jha A, Taieb D, Pacak K . Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World. Front Endocrinol (Lausanne). 2021; 12:625312. PMC: 8039528. DOI: 10.3389/fendo.2021.625312. View

12.

Carrasquillo J, Chen C, Jha A, Ling A, Lin F, Pryma D . Imaging of Pheochromocytoma and Paraganglioma. J Nucl Med. 2021; 62(8):1033-1042. PMC: 8833868. DOI: 10.2967/jnumed.120.259689. View

13.

Taieb D, Jha A, Treglia G, Pacak K . Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocr Relat Cancer. 2019; 26(11):R627-R652. PMC: 7002202. DOI: 10.1530/ERC-19-0165. View

14.

Castinetti F, Kroiss A, Kumar R, Pacak K, Taieb D . 15 YEARS OF PARAGANGLIOMA: Imaging and imaging-based treatment of pheochromocytoma and paraganglioma. Endocr Relat Cancer. 2015; 22(4):T135-45. DOI: 10.1530/ERC-15-0175. View

15.

Nolting S, Bechmann N, Taieb D, Beuschlein F, Fassnacht M, Kroiss M . Personalized Management of Pheochromocytoma and Paraganglioma. Endocr Rev. 2021; 43(2):199-239. PMC: 8905338. DOI: 10.1210/endrev/bnab019. View

16.

Zhang J, Li M, Pang Y, Wang C, Wu J, Cheng Z . Genetic Characteristics of Incidental Pheochromocytoma and Paraganglioma. J Clin Endocrinol Metab. 2022; 107(5):e1835-e1842. DOI: 10.1210/clinem/dgac058. View

17.

Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson A, Johnson A . Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell. 2017; 31(2):181-193. PMC: 5643159. DOI: 10.1016/j.ccell.2017.01.001. View

18.

Jiang J, Zhang J, Pang Y, Bechmann N, Li M, Monteagudo M . Sino-European Differences in the Genetic Landscape and Clinical Presentation of Pheochromocytoma and Paraganglioma. J Clin Endocrinol Metab. 2020; 105(10). DOI: 10.1210/clinem/dgaa502. View

19.

Shi Y, He D, Hou Y, Hu Q, Xu C, Liu Y . An alternative high output tissue microarray technique. Diagn Pathol. 2013; 8:9. PMC: 3599403. DOI: 10.1186/1746-1596-8-9. View

20.

de Herder W, Hofland L . Somatostatin receptors in pheochromocytoma. Front Horm Res. 2003; 31:145-54. DOI: 10.1159/000074662. View